Boehringer Ingelheim Vetmedica has secured the pharma licensing rights for the technology platform Artilysin from Lysando.
Artilysin developed by the research & development company Lysando, has arrived in the pharmaceutical industry.
The company is hopeful to receive significant momentum and solutions from this new substance class for the problem of multi-resistant bacteria, which also is an increasing threat to the animal world.
Artilysin are proteins that, through a physical mechanism, selectively eliminate pathogenic, multi-resistant and persisting bacteria.
By way of license, Boehringer Ingelheim Vetmedica is taking advantage of the possibilities presented by this technology.
The scope of applications for Artilysin's spans from human and animal medicine to the food industry and the area of hygiene.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Boehringer Ingelheim
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity